Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses

Cited by (200)

Items 101–200 of 200

1. Effects of dalteparin on anti‐Xa activities cannot be predicted in critically ill COVID‐19 patients
   Charlotte D.C.C. van der Heijden, Rob ter Heine, Emma J. Kooistra, Roger J. M. Brüggemann, Jesper W. J. Walburgh Schmidt, Elke P.L.M. de Grouw, Tim Frenzel, Peter Pickkers, Jenneke Leentjens · 2021 · British Journal of Clinical Pharmacology
2. Does Sample Size, Sampling Strategy, or Handling of Concentrations Below the Lower Limit of Quantification Matter When Externally Evaluating Population Pharmacokinetic Models?
   Mehdi El Hassani, Uwe Liebchen, Amélie Marsot · 2024 · European Journal of Drug Metabolism and Pharmacokinetics
3. The challenge to identify sensitive safety biomarkers of peripheral neurotoxicity in the rat: A collaborative effort across industry and academia (IMI NeuroDeRisk project)
   Laura Micheli, David Balayssac, Jérôme Busserolles, Cristelle Dalbos, Laëtitia Prival, Damien Richard, Mercédès Quintana, Lorenzo Di Cesare Mannelli, Alessandra Toti, Clara Ciampi et al. · 2024 · Toxicology
4. Mammary epithelium permeability during established lactation: associations with cytokine levels in human milk
   Katie T. Kivlighan, Sallie S. Schneider, Eva P. Browne, Brian T. Pentecost, Douglas L. Anderton, Kathleen F. Arcaro · 2024 · Frontiers in Nutrition
5. The impact of alcohol and illicit substance use on the pharmacokinetics of first-line TB drugs
   Marie Wijk, Kamunkhwala Gausi, Samantha Malatesta, Sarah E Weber, Richard Court, BRONWYN J. MYERS, Tara Carney, Charles D. H. Parry, Charles Robert Horsburgh, Laura Forsberg White et al. · 2024 · Journal of Antimicrobial Chemotherapy
6. Pharmacokinetic and pharmacodynamic analyses of terlipressin in patients with hepatorenal syndrome
   Xiaofeng Wang, Khurram Jamil · 2022 · AAPS Open
7. An ex situ and operando analysis of thiourea consumption and activity during a simulated copper electrorefining process
   Thomas Marcel Collet, Benny Wouters, Sebastiaan Eeltink, Philipp Schmidt, Kristof Ramharter, Annick Hubin · 2022 · Journal of Electroanalytical Chemistry
8. Population Pharmacokinetics of Enteric-Coated Mycophenolate Sodium in Children after Renal Transplantation and Initial Dosage Recommendation Based on Body Surface Area
   Guangfei Wang, Qiaofeng Ye, Yidie Huang, Hong Ming Xu, Zhiping Li · 2022 · Computational and Mathematical Methods in Medicine
9. Translational Pharmacokinetic‐Pharmacodynamic Modeling and Simulation: Optimizing 5‐Fluorouracil Dosing in Children With Pediatric Ependymoma
   Vinay M. Daryani, Yogesh T. Patel, Michael Tagen, DC Turner, Angel Montero Carcaboso, JM Atkinson, Amar J. Gajjar, Richard J. Gilbertson, KD Wright, C. A. Stewart · 2016 · CPT Pharmacometrics & Systems Pharmacology
10. Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients
    Nastja Lunar, Marie-Christine Étienne-Grimaldi, Pauline Macaire, Fabienne Thomas, Florence Dalenc, Jean-­Marc Ferrero, Xavier B. Pivot, Gerard Alain Milano, Bernard Royer, Antonin Schmitt · 2021 · Cancer Chemotherapy and Pharmacology
11. Vancomycin population pharmacokinetics analysis in Chinese paediatric patients with varying degrees of renal function and ages: development of new practical dosing recommendations
    Jihui Chen, Xiaohui Huang, Liting Yu, Jiru Li, Rui Yang, Lixia Li, Jia Zhou, Huijuan Yao, Shuhong Bu · 2023 · Journal of Antimicrobial Chemotherapy
12. Therapeutic monitoring of lacosamide, perampanel, and zonisamide during breastfeeding
    Ivana Kacířová, Romana Uřinovská, Milan Grundmann · 2023 · Epilepsy Research
13. Effects of housing environment on oral absorption of acetaminophen in healthy Beagles
    Melanie Madsen, Hiroko Enomoto, Kristen M. Messenger, Mark G. Papich · 2021 · American Journal of Veterinary Research
14. Valproic Acid Concentrations in Mothers, Colostrum and Breastfed Infants during the Early Postpartum Period: Comparison with Concentrations Determined during Delivery and in the Mature Milk Period
    Ivana Kacířová, Milan Grundmann, Hana Brozmanová · 2021 · Pharmaceutics
15. Population pharmacokinetic modelling of febuxostat in healthy subjects and people with gout
    Bishoy Kamel, Ahmad Y. Abuhelwa, David J. R. Foster, Janna K. Duong, Garry G. Graham, Kenneth M. Williams, Kevin D. Pile, Richard Osborne Day · 2022 · British Journal of Clinical Pharmacology
16. Plasma bile acid profile analysis by liquid chromatography-tandem mass spectrometry and its application in healthy subjects and IBD patients.
    Xue-peng Gong, Dong Liu, Lu Liu, Guangjie Yang, Yong-Fang Lei, Ninghong Li, Yu-Fei Chen, Hengyi Yu, Xi-Ping Li, Dong Xiang · 2024 · Journal of Pharmaceutical and Biomedical Analysis
17. Enhancing pharmacometric modeling with full Bayesian inference and Student’s t-Based M3 Censoring: A simulated population PK study on robust handling of outliers and censored data
    Yiming Cheng, Yan Li · 2025 · Journal of Pharmaceutical Sciences
18. Can edoxaban be used at extremes of bodyweight and in patients with a creatinine clearance ≥95 ml/min? – A population pharmacokinetic analysis
    Rachel E. Clapham, Victoria Speed, Rosalind Byrne, Lara N. Roberts, Julia Czuprynska, Emma Gee, Sinead Duffy, Rachna Patel, Raj Patel, Roopen Arya et al. · 2024 · Thrombosis Research
19. Impact of Composition of Lipid-Based Formulations on First-Pass Drug Metabolism after Oral Administration
    Yusuke Tanaka, Rikuto Fukaishi, Daiki Okamoto, Takanori Kurakazu, Tokio Nakai, Haruya Yagi, Shinji Sakuma · 2025 · Molecular Pharmaceutics
20. Dosing Recommendations for Lamotrigine in Children: Evaluation Based on Previous and New Population Pharmacokinetic Models
    Manon Tauzin, Jean‐Marc Tréluyer, Rima Nabbout, Thierry Billette de Villemeur, Isabelle Desguerre, Radia Aboura, Inès Gana, Yi Zheng, Sihem Benaboud, Naïm Bouazza et al. · 2020 · The Journal of Clinical Pharmacology
21. Low and Highly Variable Exposure to Prophylactic LMWH Nadroparin in Critically Ill Patients: Back to the Drawing Board for Prophylactic Dosing?
    Jeroen Diepstraten, Anne van Rongen, Marianne P. Zijlstra, Marieke J. H. A. Kruip, Pim L. J. van der Heiden, Rob ter Heine · 2022 · Clinical Pharmacokinetics
22. Characterization, in vitro dissolution, and pharmacokinetics of different batches of efavirenz raw materials
    Danilo César Galindo Bedor, Noely Camila Tavares Cavalcanti Bedor, João Gomes Pontes Neto, Lucas José de Alencar Danda, Flávio Martins de Oliveira, Guilherme Henrique Onório de Oliveira, José Lamartine Soares‐Sobrinho, Eric Beyssac, Whocely Victor de Castro, Davi Pereira de Santana · 2021 · Drug Development and Industrial Pharmacy
23. Raman spectroscopy as a tool to accelerate development of complex medicinal products
    Panagiota Zarmpi, Dimitrios Tsikritsis, Andrew C. Watson, Jean‐Luc Vorng, Vasundhara Tyagi, Natalie A. Belsey, Elena Rantou, Priyanka Ghosh, Annette L. Bunge, Timothy J. Woodman et al. · 2025 · Journal of Controlled Release
24. Factors Influencing Monoclonal Antibody Pharmacokinetics Across Varying Immune Perturbations
    Jonathon DeBonis, Anthony E. Davis, Zeshi Wang, Cody Fell, Michael R. Diehl, Oleg A. Igoshin, Omid Veiseh A · 2025 · Journal of Controlled Release
25. A Minimal PBPK Model for Plasma and Cerebrospinal Fluid Pharmacokinetics of Trastuzumab after Intracerebroventricular Administration in Patients with HER2-Positive Brain Metastatic Localizations
    Alicja Puszkiel, Guilhem Bousquet, Françoise Stanke‐Labesque, Jeanick Stocco, Philippe Decq, Lucie Chevillard, Stéphane Goutagny, Xavier Declèves · 2023 · Pharmaceutical Research
26. Comparing two-sample log-linear exposure estimation with Bayesian model-informed precision dosing of tobramycin in adult patients with cystic fibrosis
    Dominic M. H. Tong, Maria‐Stephanie A. Hughes, Jasmine Y. Hu, Jeffrey C Pearson, David W. Kubiak, Brandon Dionne, Jasmine H. Hughes · 2025 · Antimicrobial Agents and Chemotherapy
27. Modeling and Simulation to Support Phase Ib/IIa Dose Selection for WBP216, A Long Half-Life Fully Human Monoclonal Antibody Against Interleukin-6
    Xiange Tang, Xiaofeng Zeng, Xiaoduo Guan, Rui Chen, Pei Hu · 2021 · Frontiers in Pharmacology
28. Impact of CYP2D6*2, CYP2D6*35, rs5758550, and related haplotypes on risperidone clearance in vivo
    Elisabet Størset, Line Skute Bråten, Magnus Ingelman‐Sundberg, Inger Johansson, Espen Molden, Marianne Kristiansen Kringen · 2024 · European Journal of Clinical Pharmacology
29. Pharmacokinetic analysis of modified-release metoprolol formulations: An interspecies comparison
    Elien De Thaye, Anouk Vervaeck, Eleonora Marostica, Jean Paul Remon, Jan Van Bocxlaer, Chris Vervaet, An Vermeulen · 2016 · European Journal of Pharmaceutical Sciences
30. Carbamazepine and carbamazepine-epoxide concentrations in mothers, colostrum, and breastfed newborns: Comparison with concentrations determined during delivery and in the mature milk period
    Ivana Kacířová, Milan Grundmann, Hana Brozmanová · 2022 · Biomedicine & Pharmacotherapy
31. Exposure of wild mammals to glyphosate, AMPA, and glufosinate: a case for “emerging organic contaminants”?
    Clémentine Fritsch, Brice M. R. Appenzeller, Colette Bertrand, Michaël Cœurdassier, Vincent Driget, Emilie M. Hardy, Paul Palazzi, Charline Schaeffer, Anne-Claude Goydadin, Sabrina Gaba et al. · 2025 · Peer Community Journal
32. Pharmacological and clinical monitoring in children with acute lymphoblastic leukemia treated with a biogeneric PEG‐ l ‐asparaginase product
    Cristina Matteo, Antonella Colombini, Laura Rachele Bettini, Luca Porcu, Silvia Barzaghi, Tommaso Ceruti, Daniela Silvestri, Angela Amoroso, Fabiola Dell’Acqua, Giacomo Gotti et al. · 2022 · Pediatric Blood & Cancer
33. Analysis of Parabens and Bisphenol A in Female Hair via LC-MS/MS and Its Application to a Biomonitoring Study in Southern Brazil
    Giovana Piva Peteffi, Cloé Dagnese Loredo, Camila Favretto de Souza, Roberta Zilles Hahn, Amanda Pacheco Bondan, Rafael Linden · 2025 · Chemosensors
34. Pharmacokinetics of Pegaspargase with a Limited Sampling Strategy for Asparaginase Activity Monitoring in Children with Acute Lymphoblastic Leukemia
    Cristina Matteo, Antonella Colombini, Marta Cancelliere, Tommaso Ceruti, Ilaria Fuso Nerini, Luca Porcu, Massimo Zucchetti, Daniela Silvestri, Maria Grazia Valsecchi, Rosanna Parasole et al. · 2025 · Pharmaceutics
35. Association Between Heavy Metals Exposure and Elevated High-Sensitivity C-Reactive Protein: Mediating Role of Body Mass Index
    Seong‐Uk Baek, Jin‐Ha Yoon · 2025 · Biomolecules
36. Multiple linear regression modeling with values below a lower limit of quantification – a statistical method comparison
    Lorena Hafermann, Isao Yokota, Linda Kalski, Bernd Wolfarth, Carolin Herrmann · 2026 · BMC Medical Research Methodology
37. Bridging Fixed Dose to Body Weight-based Regimen of Adalimumab in Paediatric Ulcerative Colitis Using a Pharmacometric Modelling Approach: Case Study with the Phase 3 ENVISION I Trial
    Sven Stodtmann, Mong‐Jen Chen, Lucia Siovitz, Mareike Bereswill, Andreas Lazar, Nicholas Michael Croft, Jarosław Kierkuś, William A. Faubion, Nael Mohamed Mostafa · 2022 · Journal of Crohn s and Colitis
38. Evidence for independent actions of the CRF and ghrelin systems in binge-like alcohol drinking in mice
    Rani S. Richardson, Lindsay A Kryszak, Janaina C. M. Vendruscolo, George F. Koob, Lorenzo Leggio, Leandro Franco Vendruscolo · 2025 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
39. Pharmacokinetics and bioavailability after intramuscular injection of the 5‐ HT 1A serotonin agonist R‐8‐hydroxy‐2‐(di‐n‐propylamino) tetralin (8‐ OH ‐ DPAT ) in domestic goats (Capra aegagrus hircus)
    Silke Pfitzer, Andrew P. Woodward, Liesel Laubscher, K. S. Warren, Rebecca Vaughan‐Higgins, Jacobus P. Raath, Michael Laurence · 2019 · Journal of Veterinary Pharmacology and Therapeutics
40. Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP)
    Eduard Schmulenson, Cédric Bovet, Regula Theurillat, Laurent Arthur Decosterd, Carlo Rodolfo Largiadèr, Jean‐Christophe Prost, Chantal Csajka, Daniela Bärtschi, Matthias Gückenberger, Roger von Moos et al. · 2022 · British Journal of Clinical Pharmacology
41. Characterizing Enoxaparin’s Population Pharmacokinetics to Guide Dose Individualization in the Pediatric Population
    Fernando Olinto Carreño, Jacqueline G. Gerhart, Victória Etges Helfer, Jaydeep Sinha, Karan R. Kumar, Carl M. J. Kirkpatrick, Christoph Paul Vincent Hornik, Daniel González, Daniel K. Benjamin, Kanecia Zimmerman et al. · 2024 · Clinical Pharmacokinetics
42. Analysis of serum concentrations of metoprolol and its metabolite α-hydroxymetoprolol in patients with heart failure with reduced ejection fraction: a pilot study in routine health care
    Ivana Kacířová, Marie Lazárová, Romana Uřinovská, Jozef Dodulík, Jan Václavík · 2025 · Expert Review of Clinical Pharmacology
43. Pharmacokinetics and Pharmacodynamics of Atazanavir in HIV-1-Infected Children Treated With Atazanavir Powder and Ritonavir
    Heather Sevinsky, Luna Zaru, Reena Wang, Xiaohui Xu, Cheryl Pikora, Todd A. Correll, Timothy Eley · 2017 · The Pediatric Infectious Disease Journal
44. Adrenocortical carcinoma
    Madeleine H. T. Ettaieb · 2020
45. Population Pharmacokinetic Modeling of Amoxicillin in Plasma and Milk in Lactating Göttingen Minipigs – A Contribution from the ConcePTION Project
    Miao‐Chan Huang, Julia Macente, Nina Nauwelaerts, Rodolfo Hernandes Bonan, Alberto Elmi, Domenico Ventrella, Pieter Annaert · 2025 · The AAPS Journal
46. A Population Pharmacokinetic Approach to Understand the Effect of Efavirenz on CYP3A Activity in Healthy Volunteers Using Midazolam as a Probe
    Kimberly S. Collins, Blessed Winston Aruldhas, Ingrid Ferreira Metzger, Jessica Bo Li Lu, Michael A. Heathman, Sara K. Quinney, Zeruesenay Desta · 2025 · CPT Pharmacometrics & Systems Pharmacology
47. Prevalence of venous thromboembolism in patients undergoing diagnostic venous ultrasound during the first SARS-CoV-2 pandemic
    Guglielmo La Torre, Raveenjot Nagra, Haren Eranga Wijesinghe, Gowshan Rajeswaran, Jain Riya, Scerif Abdulkhaliq, Tom Barker, Arul Ganeshan, Robert J. B. Goudie, Hosaam H. Nasr et al. · 2023 · VASA
48. Population pharmacokinetic analysis reveals no impact of aprepitant on the pharmacokinetics of ifosfamide, 2-dechloroifosfamide, and 3-dechloroifosfamide
    Thibaud Valentin, Marie Lambert, Léonor Chaltiel, Ben Allal, Mourad Mseddi, Malika Yakoubi, Christine Chevreau, Maud Toulmonde, Nelly Firmin, Thomas Filleron et al. · 2023 · European Journal of Pharmaceutical Sciences
49. Confidence interval comparison: Precision of maximum likelihood estimates in LLOQ affected data
    Tanja Bülow, R.-D Hilgers, Nicole Maria Heussen · 2023 · PLoS ONE
50. Plasma SARS‐CoV‐2 RNA elimination and RAGE kinetics distinguish COVID‐19 severity
    Xiaoyan Deng, Pierre Gantner, Julia Forestell, Amélie Pagliuzza, Elsa Brunet‐Ratnasingham, Madéleine Durand, DE Kaufmann, Nicolas Chomont, Morgan Craig · 2023 · Clinical & Translational Immunology
51. Assessing Pharmacogenomic loci Associated with the Pharmacokinetics of Vamorolone in Boys with Duchenne Muscular Dystrophy
    Xiaonan Li, Daniele Sabbatini, Elena Pegoraro, Luca Bello, Paula R. Clemens, Michela Guglieri, John N. van den Anker, Jesse M. Damsker, John McCall, Utkarsh J. Dang et al. · 2024 · The Journal of Clinical Pharmacology
52. Disease–Drug–Drug Interaction of Imatinib in COVID ‐19 ARDS : A Pooled Population Pharmacokinetic Analysis
    Medhat M. Said, Job R. Schippers, Leila N. Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm Jan Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart et al. · 2025 · CPT Pharmacometrics & Systems Pharmacology
53. Population Pharmacokinetics of IV Lidocaine and its Metabolites in Adult Surgical Patients
    Keng Wah Foong, Pui San Loh, Sook Hui Chaw, Yoke Lin Lo · 2025 · Pharmaceutical Research
54. Utilizing blood inflammatory markers in alcohol studies: Considerations and recommendations for study design, sample collection, and data analysis
    Erica N. Grodin, Hollis C. Karoly, Brittney D. Browning, Leon G. Coleman, Mehdi Farokhnia, Lindsay A Kryszak, Lindsay R. Meredith, Lindsay M. Squeglia · 2025 · Neuroscience & Biobehavioral Reviews
55. Serum ocrelizumab concentrations in patients with multiple sclerosis: A cross-sectional study from routine healthcare
    M. Denisa, Ivana Kacířová, Hradilek Pavel, Matlak Patrik, Brozmanova Hana, Sistik Pavel, Blanka Kořístková, Milan Grundmann · 2025 · Multiple Sclerosis and Related Disorders
56. Development of a Limited Sampling Strategy for the Estimation of Exposure to High-Dose Etoposide After Intravenous Infusion in Pediatric Patients
    Dorota Danielak, Joanna Sobiak, Jacek Wachowiak, Franciszek Krzysztof Główka, Maria Chrzanowska · 2016 · Therapeutic Drug Monitoring
57. Analysis of Concentrations of Monomethyl Fumarate in Patients with Multiple Sclerosis: Result from Routine Health Care
    Zuzana Krska Kusnirikova, Ivana Kacířová, Veronika Pesakova, Pavel Hradílek, Hana Brozmanová, Milan Grundmann · 2024 · CNS & Neurological Disorders - Drug Targets
58. Population Pharmacokinetic Analysis of Phenytoin After Intravenous Administration of Fosphenytoin in Adult and Elderly Epileptic Patients
    Kanae Higuchi, Daiki Yamashita, Yushi Kashihara, Makoto Kakara, Takeshi Hirota, Masaaki Hirakawa, Ichiro Ieiri · 2019 · Therapeutic Drug Monitoring
59. Beta-Lactam Antibiotics Can Be Measured in the Exhaled Breath Condensate in Mechanically Ventilated Patients: A Pilot Study
    José Escalona, Dagoberto Soto, Vanessa Oviedo, Elizabeth Rivas, Nicolás Severino, Eduardo Kattan, Max Andresen, Sebastián Bravo, Roque Basoalto, María Consuelo Bachmann et al. · 2023 · Journal of Personalized Medicine
60. Population Pharmacokinetics of Cobicistat and its Effect on the Pharmacokinetics of the Anticancer Drug Olaparib
    Joanneke K. Overbeek, Nielka P. van Erp, David Marinus Burger, Alfons A den Broeder, Stijn L.W. Koolen, Alwin D. R. Huitema, Rob ter Heine · 2025 · Clinical Pharmacokinetics
61. Treats containing cannabidiol, L-tryptophan and α-casozepine have a mild stress-reducing effect in dogs
    Hannah E. Flint, Jennifer E. Weller, Alysia B. G. Hunt, Tammie King · 2025 · Frontiers in Veterinary Science
62. Targeting multiple biomarkers via high-resolution mass spectrometry outperforms single markers in distinguishing Mimosa scabrella Bentham honeydew honey
    Bibiana Silva, Kevin Tschang Neff, Sorel Tchewonpi Sagu, Tess Waldbach Braga, Luciano Valdemiro Gonzaga, Ana Carolina Oliveira Costa, Harshadrai M. Rawel · 2025 · Food Research International
63. Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV
    Lufina Tsirizani, Hylke Waalewijn, Alexander J. Szubert, Veronica Mulenga, Chishala Chabala, Mutsa Bwakura‐Dangarembizi, Moses Chitsamatanga, Diana A. Rutebarika, Victor Musiime, Mariam Kasozi et al. · 2025 · Antimicrobial Agents and Chemotherapy
64. Pharmacokinetic Similarity of Biosimiliar AVT05 Versus Reference Product Golimumab in Healthy Adults: A Double-Blind, Three-Arm, Parallel-Group Study
    Chris Wynne, Ulrike Lorch, Edrich Krantz, Rohit Katial, Thomas Ashdown, Mónica Luque, Abid Sattar, Masna Rai, Laxmikant Vashishta, Katarina Petrović et al. · 2025 · BioDrugs
65. Factors associated with treatment-resistant hypertension: results of a prospective observational study
    Mohammed Awais Hameed, Mohamed Elsadig, Shakil Ahmad, Sayeed M Haque, Charles Joseph Ferro, Paramjit Singh Gill, Indranil Dasgupta · 2025 · Journal of Hypertension
66. Pharmacokinetic and pharmacodynamic results from a randomized controlled study with the growth hormone secretagogue receptor blocker PF-5190457 in recently abstinent patients with alcohol use disorder
    Ryan E Tyler, Rabea K Pfaff, R M Naseer Khan, Anna Loftén, Ryan Zurick, Yi Arial Zeng, Oluwatobi T. Arisa, Charlotte Harvey, Fatemeh Akhlaghi, William D Figg et al. · 2025 · The International Journal of Neuropsychopharmacology
67. Exploring the effects of renal and cardiac functions on the pharmacokinetics of vancomycin in patients undergoing cardiac surgery: a population pharmacokinetic analysis
    Yinglong Ding, Ling Xue, Qiong Qin, Haoyue Huang, Yihuan Chen, Han Shen, Yanqiu Hu, Yupeng Chen, Liyan Miao, Zhenya Shen · 2026 · International Journal of Clinical Pharmacy
68. Filter substrate comparison and biodegradable flocculant dosing for a compact constructed wetland treating combined sewer overflow
    Julia Storath, Maximilian P. Born, Frank Benstöm, Thomas Wintgens · 2026 · Water Research
69. Efficacy evaluation of a fermented milk containing inactivated biomasses of Lacticaseibacillus rhamnosus and Saccharomyces cerevisiae to ameliorate the toxic effects of dietary aflatoxins and fumonisins in pigs: a pilot study
    Lucas Gabriel Dionísio Freire, Jennifer Rafaela Sá da Silva, Lucas Luiz Assis, Leandra Náira Zambelli Ramalho, Fernando Silva Ramalho, Fábio Enrique Lemos Budiño, Karina Nascimento Pereira, Rogério D’Antonio Pires, Sana Ullah, Sher Ali et al. · 2026 · Mycotoxin Research
70. Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Hepatitis C Virus-Infected Cirrhotic and Non-cirrhotic Patients: Analyses Across Nine Phase III Studies
    Sathej Gopalakrishnan, Sven Mensing, Rajeev M Menon, Jiuhong Zha · 2018 · Clinical Pharmacokinetics
71. Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis
    Qian Li, Ju Qiao, Hongzhong Jin, Benchao Chen, Zhimei He, Guoqin Wang, Xiang Ni, Max Mu Wang, Michelle Xia, Baiyong Li et al. · 2022 · Frontiers in Pharmacology
72. General Pharmacology of Anesthetic and Analgesic Drugs
    Ted Whittem, Thierry Beths, Sébastien H. Bauquier · 2024
73. The respiratory physiology of opioid immobilisation in African antelope
    Silke Pfitzer · 2019 · Murdoch University Research Portal
74. Comparison of area under the curves for vancomycin from one- and two-compartment models using sparse data
    Nyein Hsu Maung · 2020
75. Is the current therapeutic dosage of nadroparin adequate for neonates and infants under 8 months with thromboembolic disease? a population pharmacokinetic study from a national children’s medical center
    Yewei Chen, Jianger Lan, Lin Zhu, Min Dong, Yi Wang, Zhiping Li · 2024 · Frontiers in Pharmacology
76. Lipoprotein(a) and large artery atherosclerosis: Results from the BIOSIGNAL Study
    Felix Gross, Valerie Schütz, Laura P. Westphal, Corinne Inauen, Thomas Pokorny, Susanne Wegener, Andreas Rüdiger Luft, Katharina S. Spanaus, Arnold von Eckardstein, Pierre‐Jean Touboul et al. · 2024 · medRxiv
77. Plasma N-terminal pro-B-type natriuretic peptide and urinary aldosterone-to-creatinine ratio in healthy Chihuahuas
    Alberto Galizzi, Greta Dossi, Paola Pocar, V. Borromeo, Chiara Locatelli · 2024 · BMC Veterinary Research
78. Ethylated Phosphorylcholine as a New Marker for Alcohol Consumption: A Proof of Concept
    Catalina Dumitrascu, Elias Iturrospe, Els Scheir, Patrick Timmermans, Erik Fransén, Mark Van Puymbroeck, Glenn Van Nieuwenhove, Maryline Busschots, Diona D’Hondt, Alexia Van Goethem et al. · 2025 · Drug Testing and Analysis
79. Determination of serum concentrations of canrenone (active metabolite of spironolactone) in patients with heart failure with reduced ejection fraction: a cross-sectional study
    Marie Lazárová, Romana Uřinovská, Ivana Kacířová, Jozef Dodulík, Milan Grundmann, Jan Václavík · 2025 · Pharmacological Reports
80. Exposure–Response Modeling of Monthly Migraine Days for Efficacy of Atogepant in Patients With Episodic or Chronic Migraine
    Louisa Schlachter, Denise Beck, Ramesh Boinpally, Sven Stodtmann · 2025 · CPT Pharmacometrics & Systems Pharmacology
81. Associations of Accelerometer-Determined Sedentary and Physical Activity Behaviors with Heart Failure Biomarkers during Midlife: CARDIA Study
    Kelley Pettee Gabriel, Bjoern Hornikel, Erin E. Dooley, Baojiang Chen, Sylvia E. Badon, Ankeet S. Bhatt, Mercedes R. Carnethon, David R. Jacobs, Sadiya S. Khan, João A.C. Lima et al. · 2025 · Medicine & Science in Sports & Exercise
82. Plasma concentrations of the inflammatory adipokine lipocalin-2 are not affected by chronic alcohol exposure in rats or acute alcohol administration in people with alcohol use disorder
    Rani S. Richardson, Mehdi Farokhnia, Leandro Franco Vendruscolo, Lorenzo Leggio · 2025 · The American Journal of Drug and Alcohol Abuse
83. Additional file 1 of Pharmacokinetic and pharmacodynamic analyses of terlipressin in patients with hepatorenal syndrome
    Wang, Xiaofeng, Khurram Jamil · 2022 · Figshare
84. Lipoprotein(a) and large artery atherosclerosis: results from the BIOSIGNAL study
    Felix Gross, Valerie Schütz, Laura P. Westphal, Corinne Inauen, Thomas Pokorny, Susanne Wegener, Andreas Rüdiger Luft, Katharina S. Spanaus, Arnold von Eckardstein, Pierre‐Jean Touboul et al. · 2026 · Lipids in Health and Disease
85. Population Pharmacokinetic Modeling of Encorafenib in Healthy Participants and Patients with BRAF V600-Mutant Solid Tumors: A Semi-mechanistic Autoinduction Model
    Derek Z. Yang, Erik M. Hahn, Joseph A. Piscitelli, Yazdi K. Pithavala, Jennifer E. Hibma · 2026 · Clinical Pharmacokinetics
86. Reference values for the alcohol biomarker phosphatidylethanol (PEth) in the Belgian population: Insights from a nationwide microsampling study
    Kevin Vandenbroucke, Katleen Van Uytfanghe, Liesl Heughebaert, Nicolas Berger, Evy De Boosere, Christophe Pol Stove · 2026 · Drug and Alcohol Dependence Reports
87. Development and Validation of Linear Regression Models to Predict Plasma-Free Perampanel Concentrations Using Routine Clinical Data
    Rena Yamaguchi, Tatsuya Yagi, Toshiaki Suzuki, Yasuaki Mino, Takafumi Naito, Shinichiro Koizumi, Kazuhiko Kurozumi, Koji Suzuki, Junichi Kawakami · 2026 · Therapeutic Drug Monitoring
88. Machine learning combined with population pharmacokinetics: a hybrid model for predicting the plasma concentration of linezolid in critically ill pediatric patients
    Yanping Zhang, Lin Zhu, Li Shen, Guangfei Wang, Junqi Zhang, Yuehua Chen, Y H Wang, Z D Li · 2026 · Frontiers in Pharmacology
89. Metabolic fate and oral dosing feasibility of the formyl peptide receptor 2 agonist WKYMVm: An integrated analytical and kinetic modeling approach
    Seongsoo Lee, Seungah Yang, Wonseok Hu, Yoo‐Seong Jeong, Yoe‐Sik Bae, Wooin Lee · 2026 · European Journal of Pharmaceutical Sciences
90. Decoupling CAR‐T Expansion, Conversion, and Decay Timing: Physiologically Aligned Semi‐Mechanistic Modeling With Smooth Gating and a Cauchy Likelihood Residual Model
    Yiming Cheng, Yan Li · 2026 · The Journal of Clinical Pharmacology
91. Objectification of the Drug Interaction of Metoprolol and Amiodarone by Determining Their Serum Concentrations Including Metabolites: An Observational Study
    Martin Kolek, Ivana Kacířová, E. Hrudikova-Vyskocilova, Jana Ďuricová, Romana Uřinovská, Milan Grundmann · 2026 · Bratislavské lekárske listy/Bratislava medical journal
92. Fitness functions for population pharmacokinetic modeling
    Zhonghui Huang, Matthew L. Fidler, Joseph Frank Standing, Frank Kloprogge · 2026 · Research Square
93. In vitro feasibility studies for clinical microdialysis with lipophilic compounds: A case study with the antifungal posaconazole
    Amrei-Pauline Konrad, Linda B. S. Aulin, Gerd Mikus, Charlotte Kloft · 2026 · Journal of Pharmaceutical Sciences
94. Pharmacokinetic-Pharmacodynamic Modelling of Repeated Ocrelizumab Dosing in Relapsing-Remitting Multiple Sclerosis
    Trond Trætteberg Serkland, Anna-Kristina Fredheim Oma, Erik Ingmar Hallin, Mathias H. Øverås, Gro Owren Nygaard, Kjell‐Morten Myhr, Øivind Torkildsen, Susanna Röblitz, Silje Skrede · 2026 · Clinical Pharmacokinetics
95. One Model to Dose Them All: A Population Pharmacokinetic Model for Multiple Aminoglycosides Across the Human Lifespan
    Dominic M. H. Tong, Jonathan D. Faldasz, Ron J. Keizer, Jasmine H. Hughes · 2026 · The Journal of Clinical Pharmacology
96. Prospective Evaluation of Thiotepa Pharmacokinetics in Children and Young Adults Undergoing Allogeneic or Autologous Hematopoietic Cell Transplantation
    Jordan T. Brooks, Shams Ismaeil, M.A. Hughes, Beth Apsel Winger, Ying Lu, Liusheng Huang, Christine S. Higham, Kristina Nelson, Susan E. Long, Ashish O. Gupta et al. · 2026 · The Journal of Clinical Pharmacology
97. Comparing the Predictive Performance of Machine Learning Models with a Newly Developed Population Pharmacokinetic Model for Busulfan in Paediatric Patients
    Tianwu Yang, Maria Thastrup, Tania Nicole Masmas, Hilde Hylland Uhlving, Jacob Nersting, Malene Johanne Petersen, Annie Rasmussen, Kjeld Schmiegelow, Trine Meldgaard Lund · 2026 · Clinical Pharmacokinetics
98. Optimization of Cefotaxime Treatment in Intensive Care Patients: Impact of Inter- and Intra-patient Variability on Pharmacokinetics and Target Attainment
    Anthéa Deschamps, Florence Gattacceca, Olivier J. Blin, Lionel J. Velly, Romain Guilhaumou · 2026 · Clinical Pharmacokinetics
99. Developmental shift from hormonal to neural correlates of psychobehavioral problems among early adolescent boys
    正紘 清田, Eimu Shoji, Favour Omileke, 俊介 森, Kentaro Morita, Tempei Ikegame, Shuntaro Ando, Syudo Yamasaki, Atsushi Nishida, Kiyoto Kasai et al. · 2026 · Psychoneuroendocrinology
100. Population pharmacokinetics modeling of albendazole and its active metabolite, albendazole sulfoxide in mass drug administration against lymphatic filariasis
     Abdullah Alshehri, Christopher L. King, Daryl J. Murry · 2026 · Antimicrobial Agents and Chemotherapy